Biocon’s Yesafili has FDA approval, but these new switching results may decide whether eye specialists embrace it
Biocon’s new Yesafili studies add switching and subgroup evidence ahead of a planned U.S. launch in the competitive aflibercept market.
Pharma & Biotech
Pharma & Biotech
Memento Medicines launches with $93m, but can MMT-205 challenge retinal drug leaders?
Discover how Memento Medicines plans to challenge retinal drug leaders with $93 million, MMT-205 and a direct Tie2 activation strategy.
Medical Devices & Diagnostics
Can Everads Injector change how ophthalmology drugs reach the back of the eye?
Retina drugs are improving, but delivery remains the bottleneck. Everads Therapy is testing whether suprachoroidal access can change that.
Pharma & Biotech
Ollin’s next-gen VEGF/Ang2 antibody shows superiority over faricimab in Phase 1b trial
Ollin’s OLN324 outperformed faricimab in a head-to-head retinal trial. Find out how this could change first-line treatment in DME and wAMD.
Pharma & Biotech
Innovent–Ollin’s bispecific antibody OLN324 delivers superior retinal drying in DME
Ollin Biosciences and Innovent Biologics have reported positive topline results from the randomized Phase 1b JADE trial, in which OLN324 (IBI324), a next-generation VEGF/Ang2 bispecific antibody, demonstrated superior anatomical efficacy over faricimab in patients with diabetic macular edema and wet age-related macular degeneration. Conducted in over 160 patients across the United States, the head-to-head study